Trade Mark Journal No.2026/006 6 February 2026
UK00004327821 21 January 2026 (5)

International priority date claimed: 17 November 2025
(United States of America)
(99500529)
- Class 5
- Bioavailability enhancing molecular complex as an intermediate product in the manufacture of pharmaceuticals for the treatment of migraines, neurological disorders and central nervous system disorders.
Axsome Therapeutics, Inc.
Representative: Keltie LLP